NASDAQ:DRNADicerna Pharmaceuticals Stock Price, Forecast & News

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DRNA stock has increased by 36.8% and is now trading at $23.10. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) released its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.28 by $0.59. The biopharmaceutical company earned $34.03 million during the quarter, compared to analysts' expectations of $59.61 million. Dicerna Pharmaceuticals had a negative net margin of 213.04% and a negative return on equity of 74.79%. View Dicerna Pharmaceuticals' earnings history.

11 equities research analysts have issued 1 year price targets for Dicerna Pharmaceuticals' shares. Their forecasts range from $25.00 to $50.00. On average, they expect Dicerna Pharmaceuticals' stock price to reach $34.20 in the next year. This suggests a possible upside of 48.1% from the stock's current price. View analysts' price targets for Dicerna Pharmaceuticals.

Media stories about DRNA stock have trended somewhat positive on Monday, InfoTrie reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Dicerna Pharmaceuticals earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutDicerna Pharmaceuticals.

Dicerna Pharmaceuticals saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 3,040,000 shares, a drop of 15.6% from the April 30th total of 3,600,000 shares. Based on an average daily volume of 675,700 shares, the short-interest ratio is presently 4.5 days. Approximately 4.9% of the shares of the company are sold short. View Dicerna Pharmaceuticals' Current Options Chain.

Some companies that are related to Dicerna Pharmaceuticals include Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Myokardia (MYOK), Forty Seven (FTSV), Mirati Therapeutics (MRTX), Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), PPD (SDGR), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH) and Evotec (EVTCY). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Amarin (AMRN), Strongbridge Biopharma (SBBP), Arbutus Biopharma (ABUS), TG Therapeutics (TGTX), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Exelixis (EXEL), ImmunoGen (IMGN) and Array Biopharma (ARRY).

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Dicerna Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.85%), Wellington Management Group LLP (5.24%), UBS Group AG (2.92%), Eagle Asset Management Inc. (2.36%), State Street Corp (2.28%) and Driehaus Capital Management LLC (1.37%). Company insiders that own Dicerna Pharmaceuticals stock include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Brian K Halak, Dennis Langer, Douglas Fambrough, James B Weissman, John B Green and Peter Kolchinsky. View institutional ownership trends for Dicerna Pharmaceuticals.

DRNA stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Federated Hermes Inc., Emerald Mutual Fund Advisers Trust, Morgan Stanley, JPMorgan Chase & Co., EAM Investors LLC, Squarepoint Ops LLC, and WINTON GROUP Ltd. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Douglas Fambrough, James B Weissman, John B Green, and Peter Kolchinsky. View insider buying and selling activity for Dicerna Pharmaceuticals.

DRNA stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., Invesco Ltd., AXA, Assenagon Asset Management S.A., Two Sigma Advisers LP, Schroder Investment Management Group, and Connor Clark & Lunn Investment Management Ltd.. View insider buying and selling activity for Dicerna Pharmaceuticals.

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DRNA stock can currently be purchased for approximately $23.10.

Dicerna Pharmaceuticals has a market capitalization of $1.71 billion and generates $23.90 million in revenue each year. The biopharmaceutical company earns $-120,460,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe.

The official website for Dicerna Pharmaceuticals is www.dicerna.com.

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]